Bioactivity of adrenomedullin and proadrenomedullin N-terminal 20 peptide in man.
Although the biological effects of adrenomedullin (AM) and PAMP have been reported extensively in animal studies and from in-vitro experiments, relatively little information is available on responses to the hormone administered to man. This review summarizes data from the few studies carried out in man. In healthy volunteers, i.v. infusion of AM reduces arterial pressure, probably at a lower rate of administration than is required to elicit other responses. AM stimulates heart rate, cardiac output, plasma levels of cAMP, prolactin, norepinephrine and renin whilst inhibiting any concomitant response in plasma aldosterone. Little or no increase in urine volume or sodium excretion has been observed. Patients with essential hypertension differ only in showing a greater fall in arterial pressure and in the development of facial flushing and headache. In patients with heart failure or chronic renal failure, i.v. AM has similar effects to those seen in normal subjects but also induces a diuresis and natriuresis, depending on the dose administered. Infusion of AM into the brachial artery results in a dose-related increase in forearm and skin blood flow, more prominent and more dependent on endogenous nitric oxide in healthy volunteers than in patients with cardiac failure. When infused into a dorsal hand vein, AM partially reversed the venoconstrictor action of norepinephrine. Although much more information is required to clarify the role of AM under physiological and pathophysiological circumstances, it is clear that it has prominent hemodynamic and neurohormonal effects, though generally lesser urinary effects when administered short-term in doses sufficient to raise its levels in plasma to those seen in a number of clinical disorders. The only study of PAMP in man showed that its skeletal muscle vasodilator potency, when infused into the brachial artery of healthy volunteers, was less than one hundredth that of AM, and it was without effect on skin blood flow.
Nicholls
M G
MG
Department of Medicine and Nephrology, Christchurch Hospital, PO Box 4345, Christchurch, New Zealand. Barbara.griffin@chmeds.ac.nz
Lainchbury
J G
JG
Lewis
L K
LK
McGregor
D O
DO
Richards
A M
AM
Troughton
R W
RW
Yandle
T G
TG
D053607:Adrenomedullin; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D006333:Heart Failure / Q000517:prevention & control; D006801:Humans; D006973:Hypertension / Q000517:prevention & control; D006976:Hypertension, Pulmonary / Q000517:prevention & control; D007676:Kidney Failure, Chronic / Q000517:prevention & control; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*; D011506:Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D014680:Veins / Q000187:drug effects
D010446:Peptide Fragments; D010455:Peptides; D011506:Proteins; D053607:Adrenomedullin